ClearPoint Neuro (CLPT) CBO adds 1,781 ESPP shares, now holds 110,263

Rhea-AI Filing Summary

ClearPoint Neuro, Inc. Chief Business Officer L. Jeremy Stigall acquired 1,781 shares of common stock through the company’s Employee Stock Purchase Plan. These shares were purchased for $11.93 per share for the ESPP period from January 1, 2026 through June 30, 2026.

After this ESPP acquisition, Stigall directly holds a total of 110,263 shares of ClearPoint Neuro common stock. Under the ESPP terms, the purchase price was 85% of the fair market value on the first or last day of the purchase period, whichever was lower.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider STIGALL L. JEREMY

Role Chief Business Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	1,781	$11.93	$21K

Holdings After Transaction: Common Stock — 110,263 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

ESPP shares acquired: 1,781 shares ESPP purchase price: $11.93 per share Holdings after transaction: 110,263 shares +1 more

4 metrics

ESPP shares acquired 1,781 shares Common Stock acquired on June 30, 2026 via ESPP

ESPP purchase price $11.93 per share Price for ESPP purchase period Jan 1–Jun 30, 2026

Holdings after transaction 110,263 shares Total ClearPoint Neuro common shares directly held after ESPP acquisition

ESPP discount formula 85% of fair market value Applies to first or last day price of purchase period, whichever is lower

Key Terms

Employee Stock Purchase Plan, fair market value, grant/award acquisition, Common Stock

4 terms

Employee Stock Purchase Plan financial

"acquisition of the Issuer's common stock pursuant to the Employee Stock Purchase Plan ("ESPP"),"

An employee stock purchase plan is a company program that lets workers buy shares through small payroll deductions, often at a discount to the market price and after a set offering period. Think of it like a workplace savings plan that turns into ownership: it encourages employees to share in the company’s success and can create predictable buying or selling of stock that investors watch because it affects supply, demand and employee incentives.

fair market value financial

"at the lesser of 85% of the fair market value on either the first day or last day"

The price a willing buyer and a willing seller would agree on for an asset or security when neither is under pressure and both have access to the same information. Think of it as the market’s neutral estimate of what something is worth, like the price two neighbors would settle on for a car after comparing similar listings. Investors care because fair market value guides buying and selling decisions, tax reporting, portfolio valuation, and how accurately company assets are reflected in financial statements.

grant/award acquisition financial

""transaction_action": "grant/award acquisition","

Common Stock financial

""security_title": "Common Stock","

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/02/2026 - 04:06 PM Accepted by SEC EDGAR 07/02/2026 - 04:05 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

STIGALL L. JEREMY

(Last) (First) (Middle)

C/O CLEARPOINT NEURO, INC.

120 S. SIERRA AVE., SUITE 100

(Street)

SOLANA BEACH CALIFORNIA 92075

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ClearPoint Neuro, Inc. [ CLPT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Business Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/30/2026		A		1,781	A	$11.93(1)	110,263	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The reporting person is voluntarily reporting the acquisition of the Issuer's common stock pursuant to the Employee Stock Purchase Plan ("ESPP"), for the ESPP purchase period of January 1, 2026 through June 30, 2026. In accordance with the ESPP, these shares were purchased at the lesser of 85% of the fair market value on either the first day or last day of the purchase period.

	/s/ Danilo D'Alessandro, by Power of Attorney for Jeremy L. Stigall	07/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did ClearPoint Neuro (CLPT) report for L. Jeremy Stigall?

ClearPoint Neuro reported that Chief Business Officer L. Jeremy Stigall acquired 1,781 shares of common stock through the Employee Stock Purchase Plan. The transaction relates to the ESPP period from January 1, 2026 through June 30, 2026 and is a routine plan purchase.

How many ClearPoint Neuro (CLPT) shares does Jeremy Stigall hold after this Form 4?

After this ESPP transaction, Chief Business Officer L. Jeremy Stigall directly holds 110,263 shares of ClearPoint Neuro common stock. This total includes the 1,781 shares acquired under the Employee Stock Purchase Plan for the January 1 to June 30, 2026 purchase period.

At what price were Jeremy Stigall’s new CLPT shares acquired under the ESPP?

The 1,781 shares of ClearPoint Neuro common stock were acquired at $11.93 per share under the Employee Stock Purchase Plan. The ESPP specifies purchases at 85% of the fair market value on the first or last day of the purchase period, whichever is lower.

What period does the Employee Stock Purchase Plan cover in this ClearPoint Neuro (CLPT) Form 4?

The Employee Stock Purchase Plan acquisition reported in this Form 4 covers the purchase period from January 1, 2026 through June 30, 2026. Shares were bought at a discount to fair market value, consistent with the ESPP’s stated 85% pricing formula for that period.

Is Jeremy Stigall’s CLPT stock acquisition an open-market purchase or plan-based?

The transaction is plan-based, not an open-market trade. Chief Business Officer L. Jeremy Stigall acquired 1,781 ClearPoint Neuro shares through the company’s Employee Stock Purchase Plan, which applies an 85% of fair market value pricing formula over the defined purchase period.